No Picture
News

Guerbet Releases First Production Batch of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

First Batch Following FDA Approval is Manufactured by Liebel-Flarsheim™ Company LLC, a Guerbet Group company, in Raleigh, North Carolina Elucirem™ has the highest relaxivity compared to other non-specific GBCAs (gadolinium-based contrast agents) 1 Elucirem™ requires […]